Prima BioMed Limited is an Australia-based biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. The Company focuses on cancer immunotherapy research. The Company's main pipeline of products is based on the LAG-3 immune control mechanism, which plays a role in the regulation of the T cell immune response. The Company's product is a T cell immunostimulatory factor (APC activator), IMP321, for cancer chemoimmunotherapy, which has completed Phase II trials. In addition, it has developed infrastructure for a cell-based therapy manufacturing platform and taken CVac, an autologous dendritic cell-based product through Phase II clinical trials for ovarian cancer patients in remission. The Company's other products include IMP731 for autoimmune disease, and IMP701 for cancer and chronic infectious disease.